Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the importance of BRAF in melanoma.
Video Reports
Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma
Geoffrey T. Gibney, MD, co-leader, Melanoma Disease Group and a member of the Developmental Therapeutics (Phase I) program at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, MedStar Georgetown University Hospital, discusses selecting between BRAF inhibitor regimens in melanoma.
Dr. Luke on the Role of Targeted Therapy in Melanoma
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the role of targeted therapy in melanoma.
Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma
Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.